Back to RU Rubric Capital Management LP
ARQT
Showing 8 of 18 quarters
Position history for RURubric Capital Management LP's holdings in Arcutis Biotherapeutics, Inc.
Yes. Rubric Capital Management holds 8,421,577 shares of ARQT (Arcutis Biotherapeutics), worth $222.6M, as of its Q3 2026 13F filing. It increased the position by 150,000 shares (+1.8%) from Q2 2026. Rubric Capital Management has held ARQT since Q2 2022, across 18 quarterly 13F filings. ARQT is 2.1% of Rubric Capital Management's reported 13F portfolio.
Current Value
$222.6M
Current Shares
8.4M
Total Value Change
+$69.8M
Total Shares Change
-2.5M
Quarter-by-Quarter History